The purpose of this paper is to examine effects of ®nasteride 5 mg across different age groups in an ethnically diverse population of men with symptomatic benign prostatic hyperplasia (BPH) seen in community urology and primary care practices.
Introduction
Benign prostatic hyperplasia (BPH) is a condition that affects the majority of men as they age. 1 BPH is characterized by prostatic enlargement on digital rectal examination (DRE) accompanied by irritative and obstructive urinary symptoms. In many men, these symptoms can signi®cantly impact health-related quality of life. 2 The development of the prostate gland is dependent on the potent androgen dihydrotestosterone (DHT), which is produced from testosterone by the enzyme 5-a reductase. 5-a reductase is necessary for normal male sexual differentiation in utero and appears to play a role in the development of male pattern hair loss and prostatic hyperplasia in adults. 3Y4 Finasteride, a potent inhibitor of 5-a reductase, has been demonstrated to cause a marked decrease in intraprostatic DHT levels and has been shown in placebo-controlled trials to reduce prostate size, increase urinary¯ow, and improve symptoms in patients with BPH. 5Y6 Maintenance of the effect of ®nasteride for up to ®ve years has been demonstrated in long-term studies with the magnitude of response highly dependent on prostate volume.
7±10
This report analyses the ®ndings of two large prospective, double-blind, placebo-controlled randomised multicenter studies of ®nasteride 5 mg in the treatment of symptomatic BPH conducted at 269 community-based urology clinics and 93 primary care centers, respectively. Although conducted in different clinical settings, the studies were very similar except for an emphasis on recruitment of Black and Hispanic patients in the urologic clinic-based study. Thus, a combined analysis was facilitated by the common design, treatment and study procedures and provides a unique opportunity to evaluate the safety and tolerability pro®le of ®nasteride in a large ethnically and geographically diverse population. Pooling of data also allowed for analyses in prede®ned subgroups, including men younger and older than age 65 y, to determine if both groups responded similarly to treatment with ®nasteride. Since the effect of ®nasteride on urine¯ow and prostate volume had been investigated in previous trials, the present studies focused on changes in urinary symptoms and tolerability of ®nasteride in this large group of men.
Materials and Methods
Study methods have been previously described. 11, 12 In brief, following institutional review board approval and informed consent, men 45 y of age or older with a clinical diagnosis of BPH based on prostate gland enlargement on DRE and moderate-to-severe urinary symptoms (scores !8) on the American Urological Association Symptom Index (AUASI) with prostate-speci®c antigen (PSA) levels 10 ngamL (Hybritech, Inc., San Diego, Ca.) entered a 1 month single-blind placebo run-in period followed by randomisation to ®nasteride 5 mg or placebo (3 : 1 ratio) once daily for 12 months. Exclusion criteria included history or evidence of urethral stricture, previous prostatectomy or other invasive procedures to treat BPH, pelvic radiotherapy, recurrent episodes of urinary retention, chronic prostatitis, neurogenic bladder, recurrent urinary tract infections, current use of a-adrenergic receptor antagonists, or use of hormonal therapy including the prostate. Men suspected of having prostate cancer were excluded until cancer was ruled out. AUASI and BPH Impact Index (BII) were self-administered at screening, prior to randomization and at 3 month intervals to assess changes in urinary symptoms and disease speci®c quality of life, respectively. 13Y14 Patient and investigator global assessments of change in urinary status were performed at all post-randomization visits. Pre-treatment and endof-treatment PSA levels were measured in all patients. DHT was measured pre-and end-of-treatment in all patients in the primary care study and in a subset of patients in the urology study. Specimens for all laboratory tests were analysed in designated central laboratories. Occurrence of adverse experiences and relationship to study drug were assessed at each visit.
Chi-square or analysis of variance techniques were used to compare studies at baseline for demographics (for example, age, race), baseline AUASI and symptom severity. Mean differences in age and baseline AUASI were within protocol-de®ned levels of clinical concern (`3 y and 0.5 point difference between studies, respectively). No treatment-by-study interactions were observed. Therefore, studies were considered acceptable for pooling.
Changes from baseline in AUASI and BII were evaluated using Analysis of Covariance (ANCOVA) techniques. The model included treatment, protocol, and treatment-by-protocol interaction and baseline AUASI as a covariate to adjust for observed differences in baseline AUASI between treatment groups. The 95% con®dence ef®cacy intervals were also calculated. Serum DHT and PSA were analyzed similarly. Patient and investigator global assessments at Month 12 were categorized as worseasame or better and evaluated using the Cochran± Mantel±Haenszel test. The percentage of patients with adverse experiences and speci®c events such as prostate cancer were compared using Cochran±Mantel±Haenszel chi-square tests controlling for protocol.
The primary ef®cacy endpoint in both studies was change from baseline in AUASI. Each study was designed to have b95% power to detect a 1 point difference between treatment groups in change from baseline as statistically signi®cant at the 0.05 level. All patients treated who had at least one measurement during therapy (regardless of adherence to protocol) were included in the ef®cacy analysis; a patient's last value was carried forward to the Month 12 analysis if the patient withdrew early. Safety assessments were summarized for all randomized patients who received at least one dose of study drug.
Results
Demographic characteristics are shown in Table 1 . Overall representation of Blacks and Hispanics was approximately 11 and 9%, respectively. Patients in other raciala ethnic groups were included with Caucasians in most analyses.
Ef®cacy
Despite pooling of data, statistical power for tests of the observed treatment differences for Blacks and Hispanics was below 60%; therefore, results within ethnic subgroups are presented without regard for statistical signi®cance.
Baseline AUASI for all patients treated was 18.8 in the ®nasteride group and 18.3 in the placebo group. Month 12 adjusted mean changes in AUASI were 74.77 in the ®nasteride group and 73.59 in the placebo group (P`0.01 between treatments). For Caucasiansaothers, Blacks, and Hispanics, Month 12 adjusted mean changes in AUASI in the ®nasteride groups were 74.62, 75.38, and 75.38, respectively; placebo changes were 73.40, 73.51, and 75.81, respectively.
Symptom score changes within age subgroups are shown in Figure 1 . Baseline AUASI for men age 42±64 y was 19.2 in the ®nasteride group and 18.7 in the placebo group; for patients age 65 y and greater, these scores were 18.4 and 18.0, respectively. Month 12 adjusted mean changes for ®nasteride-treated patients were comparable in the two age groups (75.12 and 74.43, respectively) and were signi®cantly different from placebo (P`0.01 for both age groups); percentage changes from baseline were 27% and 24%, respectively. In addition, statistically signi®cant differences in adjusted mean changes from baseline in the BPH Impact Index (BII) were noted in favor of ®nasteride at Months 9 and 12 for all patients treated. Within age subgroups, Month 12 improvement in BII was statistically signi®cant for ®nasteride-treated patients age 42±64 y, but not for those age 65 y and over. Within ethnic groups, ®nasteride-treated patients experienced greater improvement in BII.
For patient global assessments at Month 12, 52.9% of patients in the ®nasteride group experienced improvement compared to 42.7% of patients receiving placebo (P`0.01). Within age subgroups, 56% of ®nasteride-treated patients age 42±64 y, as well as 50% of these patients age 65 y and over, felt`better' at Month 12 compared to baseline. Within ethnic groups, 65.2% of Blacks and 62.6% of Hispanics in the ®nasteride groups felt`better'. For investigator global assessments, 53.2% of ®nasteride-treated patients were considered improved by investigators at Month 12 compared to 44.6% of placebo patients (P`0.01). Percentages of ®nasteride-treated patients considered improved by investigators were comparable in the subgroups of patients who were age Finasteride in symptomatic BPH CA Byrnes et al 42±64 y (55.7%) and age 65 y and over (50.8%). Proportions of Blacks and Hispanics rated improved were 61.6% and 59.3%, respectively.
Month 12 median percentage changes in DHT were 771.1% in the ®nasteride group overall compared to 0.0% in the placebo group (P`0.01). Similar reductions were noted in the subgroups of men age 42 to 64 y and age 65 y and over (769.8% and 772.2%, respectively) and among Caucasianaother, Black and Hispanic patients treated with ®nasteride (771.1%, 768.3% and 772.5%, respectively). Table 2 summarises clinical adverse experiences for randomised patients in the overall population and within age subgroups. Approximately 50% of patients in each treatment group reported a history of sexual dysfunction at baseline. Only 1.8% of ®nasteride-treated patients (v 0.9% on placebo) withdrew due to a drug-related sexual adverse experience. The tolerability pro®le of ®nasteride appeared similar in each ethnic and age subgroup. For example, the differences from placebo in incidence of erectile dysfunction considered drug-related were 4.1%, 3.6% and 3.2% in Caucasiansaothers, Blacks and Hispanics, respectively.
Tolerability
One percent of patients treated with ®nasteride 5 mg reported drug-related gynecomastia or breast enlargement (placebo rate 0.2%). Incidence of the diagnosis of prostate cancer was 0.4% in both ®nasteride and placebo groups. Incidence of trans urethral resection of the prostate (TURP) was 1.2% in the ®nasteride group and 1.1% in the placebo group. 
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Effect on PSA
Mean baseline values of PSA in the ®nasteride treatment groups were 2.6 ngaml for Caucasiansaothers, 2.5 ngaml for Blacks, and 2.5 ngaml for Hispanics. Median percent reductions in serum PSA at Month 12 for Caucasianaother, Black and Hispanic men in the ®nasteride treatment groups were 750.0%, 746.7% and 747.6%, respectively. Adjusted mean changes in PSA at Month 12 in these groups were 71.2 ngaml, 71.0 ngaml and 71.1 ngaml, respectively. Similar median percent and mean changes were noted in the subset of men age 42 to 64 y (746.0% and 71.0 ngaml, respectively), and in the group age 65 y and over (752.2% and 71.3 ngaml, respectively). The cumulative percentages of ®nasteride-treated patients at each level of PSA at baseline and at study end (multiplied by 2) are shown in Figure 2 for Caucasians, Blacks and Hispanics. To properly examine ®nasteride's effect on PSA in men with BPH, patients diagnosed with prostate cancer (n 14) were excluded from these analyses. In each ethnic group the cumulative distribution of PSA levels at baseline is nearly identical to the cumulative distribution of twice the PSA level after approximately 12 months of treatment.
Comment
The purpose of these studies was to acquire additional data comparing ®nasteride 5 mg to placebo in an ethnically diverse population of US men with symptomatic BPH seeking treatment from either community-based urologists or primary care physicians. Individual study results con®rmed previous ®ndings of symptom improvement accompanied by clinically relevant changes in global assessments of urologic status by both patients and investigators. 11, 12 Long-term maintenance of effect of ®nasteride has been well documented in previous studies.
7±9 These data are especially important since, given the chronic nature of BPH, effects of therapy in this disease should be studied over periods of at least one year and results interpreted in light of natural history.
This combined analysis of two 1 year studies provided an opportunity to evaluate ®nasteride in a large number of men with BPH and to perform meaningful statistical analysis in subgroups of men younger and older than age 65 y. It has been established that the effect of ®nasteride is dependent on baseline prostate volume, with men with larger glands experiencing greater improvement in symptoms than men with relatively smaller glands. 10 Given the known age-related increase in prostate size, one might have expected different cohorts of men to respond differently to ®nasteride therapy based on age. Our data show that men age 42±64 y (mean age 57 y) and those age 65± 91 y (mean age 71 y) experienced similar improvements in urinary symptoms and global assessments of change in urologic status. These results are likely due to the study requirement that all men have prostate gland enlargement upon entry. Therefore, whether identi®ed by urologists or primary care physicians, the presence of prostate gland enlargement on DRE may help identify appropriate candidates for treatment with ®nasteride, regardless of Incidence of adverse experiences was also comparable in the two age groups. Withdrawal due to drug-related sexual adverse experiences was only 2.4% in men age 42± 64 y and 1.3% in men age 65 y and older. Thus, ®nasteride 5 mg appears to be a well-tolerated therapy for symptomatic BPH, regardless of age. A previous longer-term study con®rmed that sexual adverse events resolved despite continued treatment in 60% of patients who reported them. 7 Despite pooling of data, sample sizes attained for Black and Hispanic men were not adequate to detect treatment effects with suf®cient power within these subgroups to draw meaningful conclusions. In the case of Hispanics, the AUASI ®ndings may be due to inadequate responsiveness of the instrument. Although statistically signi®-cant and consistent differences between treatments were observed in other subgroups, and previous validations of the AUASI support the ability of the instrument to measure response to therapy, 13 the AUASI has only recently been validated in Spanish in Hispanic men and performance characteristics of the instrument may differ in this population. 16 Although recruitment of the targeted ethnic groups fell short of anticipated goals, enrollment of approximately 11% Black and 9% Hispanic men closely re¯ects the proportion of the US population represented by these ethnic groups (12% and 9%, respectively), 17 and data from these men provide important insights to the tolerability pro®le and effect of ®nasteride on serum PSA in these patients. Based on these data, ®nasteride is generally well tolerated by Caucasian, Black and Hispanic men, with very few men in any ethnic group discontinuing therapy due to a drug-related sexual adverse experience. In addition, reductions in PSA were comparable regardless of ethnic group. Median end-of-treatment values of PSA approximated half of pre-treatment values in each ethnic group, similar to the effect previously demonstrated in BPH study populations comprised largely of Caucasian men. 18, 19 These data thus provide further support to the recommendation that PSA values be doubled following several months of ®nasteride therapy for comparison to normal references ranges in untreated men with BPH.
20,21
Conclusions
Data from these controlled clinical trials in an ethnically diverse population demonstrate the favourable ef®cacy and tolerability pro®le of ®nasteride in the treatment of symptomatic BPH. In the presence of prostate gland enlargement, men age 42±64 y and those age 65 y and older respond similarly to treatment with ®nasteride.
